B-intervention	0	13	Anthracycline
O	14	19	could
O	20	22	be
O	23	32	essential
O	33	36	for
O	37	43	triple
O	43	44	-
O	44	52	negative
O	53	59	breast
O	60	66	cancer
O	66	67	:
O	68	69	A
O	70	80	randomised
O	81	86	phase
O	87	89	II
O	90	95	study
O	96	98	by
O	99	102	the
B-location	103	111	Kanagawa
O	112	118	Breast
O	119	127	Oncology
O	128	133	Group
O	134	135	(
O	135	139	KBOG
O	139	140	)
O	141	145	1101
O	145	146	.

O	147	149	It
O	150	152	is
O	153	162	important
O	163	165	to
O	166	175	determine
O	176	183	whether
O	184	197	anthracycline
O	197	198	-
O	198	208	containing
O	209	217	regimens
O	218	220	or
O	221	227	taxane
O	227	228	-
O	228	238	containing
O	239	247	regimens
O	248	251	are
O	252	256	more
O	257	266	effective
O	267	269	in
O	270	280	individual
O	281	289	patients
O	289	290	.

O	291	294	The
O	295	302	present
O	303	308	study
O	309	317	compared
O	318	321	the
O	322	330	efficacy
O	331	333	of
O	334	337	six
O	338	344	cycles
O	345	347	of
O	348	357	docetaxel
O	358	361	and
O	362	378	cyclophosphamide
O	379	380	(
O	380	383	TC6
O	383	384	)
O	385	389	with
O	390	394	that
O	395	397	of
O	398	403	three
O	404	410	cycles
O	411	413	of
O	414	415	5
O	415	416	-
O	416	428	fluorouracil
O	428	429	,
O	430	440	epirubicin
O	441	444	and
O	445	461	cyclophosphamide
O	462	470	followed
O	471	473	by
O	474	483	docetaxel
O	484	485	(
O	485	488	FEC
O	488	489	-
O	489	490	D
O	490	491	)
O	492	494	in
B-ethinicity	495	503	Japanese
O	504	512	patients
O	513	517	with
O	518	525	hormone
O	526	534	receptor
O	535	536	(
O	536	538	HR
O	538	539	)
O	539	540	-
O	540	548	negative
O	549	555	breast
O	556	562	cancer
O	563	564	(
O	564	566	BC
O	566	567	)
O	568	570	to
O	571	579	identify
O	580	588	subtypes
O	589	598	requiring
O	599	612	anthracycline
O	613	622	treatment
O	622	623	.

O	624	627	The
O	628	633	study
O	634	642	included
B-total-participants	643	646	103
O	647	655	patients
O	656	660	with
O	661	669	operable
O	670	672	HR
O	672	673	-
O	673	681	negative
O	682	684	BC
O	684	685	.

O	686	688	Of
O	689	694	these
O	695	703	patients
B-intervention-participants	704	706	53
O	707	715	received
O	716	719	FEC
O	719	720	-
O	720	721	D
O	722	725	and
B-control-participants	726	728	50
O	729	737	received
B-control	738	741	TC6
I-control	741	742	.

O	743	746	The
O	747	754	primary
O	755	763	endpoint
O	764	767	was
B-outcome-Measure	768	780	pathological
I-outcome-Measure	781	789	complete
I-outcome-Measure	790	798	response
I-outcome-Measure	799	800	(
I-outcome-Measure	800	803	pCR
I-outcome-Measure	803	804	)
O	804	805	.

O	806	809	The
O	810	819	secondary
O	820	829	endpoints
O	830	834	were
B-outcome-Measure	835	841	safety
O	841	842	,
B-outcome-Measure	843	849	breast
I-outcome-Measure	849	850	-
I-outcome-Measure	850	860	conserving
I-outcome-Measure	861	868	surgery
O	868	869	,
B-outcome-Measure	870	877	disease
I-outcome-Measure	877	878	-
I-outcome-Measure	878	882	free
I-outcome-Measure	883	891	survival
I-outcome-Measure	892	893	(
I-outcome-Measure	893	896	DFS
I-outcome-Measure	896	897	)
O	898	901	and
B-outcome-Measure	902	909	overall
I-outcome-Measure	910	918	survival
I-outcome-Measure	919	920	(
I-outcome-Measure	920	922	OS
I-outcome-Measure	922	923	)
O	923	924	.

O	925	928	The
O	929	939	predictive
O	940	947	factors
O	948	951	for
O	952	956	each
O	957	964	regimen
O	965	969	were
O	970	979	evaluated
O	979	980	.

O	981	983	Of
O	984	987	the
B-total-participants	988	991	103
O	992	1000	patients
O	1000	1001	,
B-total-participants	1002	1004	97
O	1005	1014	completed
O	1015	1018	the
O	1019	1024	study
O	1025	1026	(
O	1026	1029	FEC
O	1029	1030	-
O	1030	1031	D
O	1031	1032	,
B-intervention-participants	1033	1035	50
O	1036	1044	patients
O	1044	1045	;
O	1046	1049	TC6
O	1049	1050	,
B-control-participants	1051	1053	47
O	1054	1062	patients
O	1062	1063	)
O	1063	1064	.

O	1065	1068	The
B-outcome	1069	1072	pCR
I-outcome	1073	1077	rate
O	1078	1081	was
O	1082	1088	higher
O	1089	1093	with
O	1094	1097	FEC
O	1097	1098	-
O	1098	1099	D
O	1100	1101	(
B-iv-bin-percent	1101	1103	36
I-iv-bin-percent	1103	1104	%
O	1104	1105	)
O	1106	1110	than
O	1111	1115	with
O	1116	1119	TC6
O	1120	1121	(
B-cv-bin-percent	1121	1123	25
I-cv-bin-percent	1123	1124	.
I-cv-bin-percent	1124	1125	5
I-cv-bin-percent	1125	1126	%
O	1126	1127	)
O	1127	1128	;
O	1129	1136	however
O	1136	1137	,
O	1138	1141	the
O	1142	1152	difference
O	1153	1156	was
O	1157	1160	not
O	1161	1172	significant
O	1173	1174	(
O	1174	1175	P
O	1176	1177	=
O	1178	1179	0
O	1179	1180	.
O	1180	1183	265
O	1183	1184	)
O	1184	1185	.

O	1186	1189	TC6
O	1190	1193	was
B-outcome	1194	1199	safer
O	1200	1204	than
O	1205	1208	FEC
O	1208	1209	-
O	1209	1210	D
O	1210	1211	,
O	1212	1214	as
O	1215	1218	the
O	1219	1226	adverse
O	1227	1233	events
O	1234	1238	with
O	1239	1248	docetaxel
O	1249	1251	in
O	1252	1255	the
O	1256	1259	FEC
O	1259	1260	-
O	1260	1261	D
O	1262	1269	regimen
O	1270	1274	were
O	1275	1282	similar
O	1283	1285	to
O	1286	1291	those
O	1292	1296	with
O	1297	1300	the
O	1301	1304	TC6
O	1305	1312	regimen
O	1312	1313	.

B-outcome	1314	1319	Among
I-outcome	1320	1328	patients
I-outcome	1329	1333	with
I-outcome	1334	1339	basal
I-outcome	1340	1342	BC
O	1342	1343	,
O	1344	1347	the
B-outcome	1348	1351	pCR
I-outcome	1352	1356	rate
O	1357	1360	was
O	1361	1374	significantly
O	1375	1381	higher
O	1382	1386	with
O	1387	1390	FEC
O	1390	1391	-
O	1391	1392	D
O	1393	1394	(
B-iv-bin-percent	1394	1396	42
I-iv-bin-percent	1396	1397	.
I-iv-bin-percent	1397	1398	9
I-iv-bin-percent	1398	1399	%
O	1399	1400	)
O	1401	1405	than
O	1406	1410	with
O	1411	1414	TC6
O	1415	1416	(
B-cv-bin-percent	1416	1418	13
I-cv-bin-percent	1418	1419	.
I-cv-bin-percent	1419	1420	6
I-cv-bin-percent	1420	1421	%
O	1421	1422	;
O	1423	1424	P
O	1425	1426	=
O	1427	1428	0
O	1428	1429	.
O	1429	1432	033
O	1432	1433	)
O	1433	1434	.

B-outcome	1435	1440	Among
I-outcome	1441	1449	patients
I-outcome	1450	1454	with
I-outcome	1455	1461	triple
I-outcome	1461	1462	-
I-outcome	1462	1470	negative
I-outcome	1471	1477	breast
I-outcome	1478	1484	cancer
I-outcome	1485	1486	(
I-outcome	1486	1490	TNBC
I-outcome	1490	1491	)
O	1491	1492	,
O	1493	1496	the
B-outcome	1497	1500	DFS
O	1501	1504	and
B-outcome	1505	1507	OS
O	1508	1512	were
O	1513	1526	significantly
O	1527	1533	better
O	1534	1538	with
O	1539	1542	FEC
O	1542	1543	-
O	1543	1544	D
O	1545	1549	than
O	1550	1554	with
O	1555	1558	TC6
O	1559	1560	(
O	1560	1561	P
O	1562	1563	=
O	1564	1565	0
O	1565	1566	.
O	1566	1569	016
O	1570	1573	and
O	1574	1575	P
O	1576	1577	=
O	1578	1579	0
O	1579	1580	.
O	1580	1583	034
O	1583	1584	,
O	1585	1597	respectively
O	1597	1598	)
O	1598	1599	.

O	1600	1603	TC6
O	1604	1607	was
O	1608	1611	not
O	1612	1614	as
O	1615	1624	effective
O	1625	1627	as
O	1628	1631	FEC
O	1631	1632	-
O	1632	1633	D
O	1634	1637	for
O	1638	1646	treating
O	1647	1649	HR
O	1649	1650	-
O	1650	1658	negative
O	1659	1661	BC
O	1661	1662	,
O	1663	1665	as
O	1666	1669	TC6
O	1670	1673	was
O	1674	1677	not
O	1678	1688	sufficient
O	1689	1691	to
O	1692	1697	treat
O	1698	1702	TNBC
O	1702	1703	,
O	1704	1716	particularly
O	1717	1720	the
O	1721	1726	basal
O	1727	1734	subtype
O	1734	1735	.

O	1736	1739	Our
O	1740	1748	findings
O	1749	1756	suggest
O	1757	1761	that
O	1762	1776	anthracyclines
O	1777	1780	are
O	1781	1787	better
O	1788	1797	treatment
O	1798	1805	options
O	1806	1810	than
O	1811	1818	taxanes
O	1819	1822	for
O	1823	1828	basal
O	1829	1831	BC
O	1831	1832	.
